In:
Cancer Research, American Association for Cancer Research (AACR), Vol. 70, No. 8_Supplement ( 2010-04-15), p. 2794-2794
Abstract:
Prostate gland is considered as an androgen-dependent organ, however it is now recognized that estrogens and their receptors are involved in the normal and abnormal growth of the prostate gland. The aim of this study was to evaluate urinary estrogens and estrogen metabolites (EMs) as a biomarker for prostate cancer risk and identify factors that affect EM levels in urine. Using a liquid chromatography-tandem mass spectrometry method, urinary concentration of 15 EMs was determined in 77 prostate cancer cases, 77 healthy controls and 37 subjects that underwent biopsy and confirmed to be cancer-free (biopsy controls). Multivariate Analysis of Variance (MANOVA) was used to identify the interactions among the EM levels and their association to case control status. Wilcoxon rank-sum test was used to compare urinary EM concentrations individually by case status. Results showed that the 3 groups were comparable when MANOVA testing was applied. Ranking of EM concentrations showed that the catechol estrogen 4-OHE1 was relatively more abundant in prostate cancer patients compared to participants without cancer. Univariate analysis showed a tendency for the metabolites with high estrogenic activity, namely16-KE2 and 17-epiE3 to be secreted in lower amounts among prostate cancer patients. Multivariate logistic regression analysis confirmed that having low 16-KE2 (based on median of healthy controls) increased risk of prostate cancer with an adjusted odds ratio (OR) of 1.97 (95% CI, 0.86-4.52). A significant trend of increasing risk with lower 16-KE2 levels was also observed (P-for-trend = 0.02), with OR for the highest quartile of 4.62 (95% CI =1.34-15.99) compared to the lowest quartile. To identify factors that affect EM levels, we performed analysis among the healthy controls; being a current smoker was associated with a significant increase in the 2-hydroxy products 2-OHE1 and 2-MeOE1 and a marginal increase in the 2-OHE1/16α-OHE1 ratio. Age, body Mass Index (BMI), presence of diabetes, family history of prostate cancer or presence of BPH did not affect estrogen levels in our population. Our study did not allow stratified analysis by race due to the small numbers of non-Caucasian subjects. To conclude, our findings encourage further investigation of urinary estrogens and EMs as biomarkers for prostate cancer risk assessment. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2794.
Type of Medium:
Online Resource
ISSN:
0008-5472
,
1538-7445
DOI:
10.1158/1538-7445.AM10-2794
Language:
English
Publisher:
American Association for Cancer Research (AACR)
Publication Date:
2010
detail.hit.zdb_id:
2036785-5
detail.hit.zdb_id:
1432-1
detail.hit.zdb_id:
410466-3
Permalink